NCT00017550已完成2 期
An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)
Genzyme, a Sanofi Company54 个研究点 分布在 2 个国家开始时间: 2000年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 试验地点
- 54
研究概览
简要总结
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome.
PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.
详细描述
OBJECTIVES:
- Compare the clinical response rate of patients with early myelodysplastic syndrome treated with rabbit anti-thymocyte globulin vs standard supportive care.
- Evaluate the safety of anti-thymocyte globulin in these patients.
- Compare the time to and duration of clinical response, rates of partial response and therapy failure, and rate of disease progression in patients treated with these regimens.
- Compare the ECOG performance score, number of transfusions and/or growth factor use, and maximum time between transfusions in patients treated with these regimens.
- Compare the infection risk, use of medical resources, and quality of clinical response in patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to myelodysplastic syndrome (MDS) subtype (refractory anemia (RA) vs RA with excess blasts or hypocellular MDS). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive rabbit anti-thymocyte globulin (ATG) IV over at least 8-12 hours on days 1-4.
- Arm II: Patients receive standard supportive therapy for 6 months. At the end of 6 months, patients may receive ATG as in arm I.
Patients are followed for 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed early myelodysplastic syndrome (MDS) with less than 10% bone marrow blasts
- •Refractory anemia (RA)
- •RA with excess blasts (RAEB)
- •Hypocellular myelodysplasia
- •Low or intermediate-1 prognostic risk
- •Transfusion-dependent
- •Need for 2 or more units of red blood cells or platelets per month for 2 or more months prior to study OR
- •History of prior transfusions and 2 consecutive (at least 21 days apart) hemoglobin levels less than 8.0 g/dL or platelet counts less than 20,000/mm^3 during the past 2 months
- •Hemoglobin no greater than 12.0 g/dL after prior transfusion
- •No myelosclerosis occupying more than 30% of bone marrow space
- •No RA with ringed sideroblasts, RAEB in transformation, or chronic myelomonocytic leukemia
- •No therapy-related MDS
- •No history of immune-related hematologic disorder (e.g., idiopathic thrombocytopenic purpura)
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •At least 3 months
- •Hematopoietic:
- •See Disease Characteristics
- •No other causes of cytopenia unrelated to MDS (e.g., gastrointestinal blood loss)
- •Iron present on marrow examination OR
- •Transferrin saturation at least 20% and ferritin at least 50 ng/mL
- •Bilirubin no greater than 2 mg/dL OR
- •SGOT/SGPT no greater than 2 times normal
- •No active or chronic hepatitis B or C
- •Creatinine no greater than 2 mg/dL
- •Cardiovascular:
- •No symptomatic cardiac disease
- •No congestive heart failure (even if medically controlled)
- •No myocardial infarction within the past 6 months
- •No severe pulmonary disease
- •If history of pulmonary insufficiency, must have pO_2 at least 90 mm/Hg on room air or pCO_2 no greater than 40 mm/Hg
- •No history of unresolved B12 or folate deficiency since diagnosis of MDS
- •No untreated acute or chronic infection (afebrile for 7 days without antibiotics prior to study)
- •No active or chronic HIV
- •No concurrent cytomegalovirus infection
- •No other malignancy within the past 2 years except adequately treated localized squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
- •No concurrent drug or alcohol abuse
- •No significant medical or psychosocial problems
- •No known allergy to rabbit protein
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •At least 8 weeks since prior biologic agents, colony-stimulating factors, or epoetin alfa for MDS
- •At least 8 weeks since other prior investigational biologic agents
- •No prior or concurrent bone marrow transplantation
- 另有 16 项未显示
排除标准
- 未提供
研究者
研究点 (54)
Loading locations...
相似试验
已完成
2 期
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic SyndromeMyelodysplastic SyndromesLeukemiaNCT00016419SWOG Cancer Research Network130
已完成
2 期
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow TransplantationGraft Versus Host DiseaseMyelodysplastic SyndromesLeukemiaNCT00004255Chimeric Therapies
Unknown
2 期
Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow FailureNonmalignant NeoplasmNCT00895739Federico II University50
已完成
不适用
Prospective Randomized Controled Study on the Outcome of Greenhouse Tec in the Arthroscopic Treatment of Small to Medium Rotator Cuff TearBone Marrow StimulatingModified Suture BridgeNCT04695626Beijing Jishuitan Hospital72
已完成
2 期
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic AnemiaAplastic AnemiaNCT00065260National Heart, Lung, and Blood Institute (NHLBI)54